Cell-based Biological Reagents Market Report 2026

The cell-based biological reagents market size has grown strongly in recent years. It will grow from $13.78 billion in 2025 to $14.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to expansion of drug discovery research activities, growth in pharmaceutical R&D spending, increasing use of cell-based assays in toxicity testing, advancements in cell culture technologies, rising adoption of standardized biological reagents.

The cell-based biological reagents market size is expected to see strong growth in the next few years. It will grow to $20.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for predictive in vitro models, expansion of personalized medicine research, growing use of AI-driven drug screening, rising investments in regenerative medicine studies, increasing focus on complex disease modeling. Major trends in the forecast period include increasing adoption of 3d cell culture and assay platforms, rising use of gene-edited and reporter cell lines, growing demand for high-throughput cell-based screening, expansion of stem cell and primary cell applications, enhanced focus on physiologically relevant models.

The rising focus on cell and gene therapies is anticipated to drive the growth of the cell-based biological reagents market in the coming years. Cell and gene therapies refer to treatments that employ living cells or genetic material to repair, replace, or modify damaged cells or genes to treat or cure diseases. The use of cell and gene therapies is increasing due to the rising prevalence of rare and genetic disorders, as these therapies can target root causes at the cellular or genetic level, offering potential cures where conventional treatments only manage symptoms. Cell-based biological reagents support cell and gene therapies by providing the necessary tools and materials to culture, modify, and deliver therapeutic cells or genetic material effectively. For example, in March 2024, according to IQVIA Holdings Inc., a US-based healthcare company specializing in clinical research services and analytics, global spending on cell and gene therapies surged to $5.9 billion in 2023, reflecting an increase of 38% from 2022. Therefore, the rising focus on cell and gene therapies is driving the growth of the cell-based biological reagents market.

Companies operating in the cell-based biological reagents market are focusing on developing human-induced pluripotent stem cell (iPSC) research products to advance drug discovery, disease modeling, and regenerative medicine applications. Human-induced pluripotent stem cell (iPSC) research products refer to integrated tools and workflows that enable the generation, maintenance, differentiation, and analysis of iPSCs for applications in biomedical research, including drug testing, disease modeling, and cell therapy development. For example, in July 2024, BioServe Biotechnologies (India) Private Limited, an India-based biotechnology company, launched an advanced stem cell product line to advance regenerative medicine and drug development research. It advances biotech research through reliable iPSC generation, 3D organoid cultures, and targeted differentiation tools, minimizing variability in experiments. They streamline drug discovery by offering human-specific models that cut animal testing and speed up toxicity assessments for faster therapy development. Ultimately, they empower personalized medicine, enabling tissue regeneration for diseases such as diabetes or heart failure while slashing costs and rejection risks.

In April 2023, AnaBios Corporation, a US-based biotechnology company, acquired Cell Systems Inc. for an undisclosed amount. Through this acquisition, AnaBios aims to expand its human tissue and cell-based reagent portfolio to accelerate drug discovery and improve biologically relevant research tools for pharmaceutical, biotech, and academic clients. Cell Systems Inc. is a US-based provider of human primary cells and cell culture media offering cell-based biological reagents.

Major companies operating in the cell-based biological reagents market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Corp., Danaher Corporation, GE Healthcare, Becton, Dickinson And Company, Corning Incorporated, Lonza Group Ltd., Agilent Technologies Inc., Sartorius AG, Revvity Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec, Abcam plc, Promega Corporation, Takara Bio Inc., R&D Systems Inc., MP Biomedicals, Sino Biological, Cell Signaling Technology Inc., InvivoGen, Tocris Bioscience, and OPM Biosciences.

Tariffs are impacting the cell-based biological reagents market by increasing costs of imported cell culture media, growth factors, assay kits, laboratory consumables, and advanced cell processing equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported reagents, while Asia-Pacific faces pricing pressure on reagent exports. These tariffs are increasing research costs and affecting procurement strategies. However, they are also driving local reagent manufacturing, regional supplier development, and investment in domestic life science production capabilities.

The cell-based biological reagents market research report is one of a series of new reports that provides cell-based biological reagents market statistics, including cell-based biological reagents industry global market size, regional shares, competitors with a cell-based biological reagents market share, detailed cell-based biological reagents market segments, market trends and opportunities, and any further data you may need to thrive in the cell-based biological reagents industry. This cell-based biological reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell-based biological reagents consist of living cells or biologically active substances derived from cells that are utilized in laboratory research, diagnostic applications, and pharmaceutical development to study cellular behavior, disease processes, and intricate biological mechanisms under controlled conditions. They allow accurate evaluation of drug effectiveness, toxicity profiles, signaling pathways, metabolic activity, and gene expression, enabling dependable biological assays, therapeutic screening, and advances in biomedical research.

The primary product types of cell-based biological reagents include assay kits, cell lines, reagents, and other product types. Assay kits refer to ready-to-use kits that enable researchers to evaluate cellular responses, examine molecular interactions, or test biological activities in a controlled environment. These products utilize technologies such as two-dimensional cell culture, three-dimensional cell culture, high-throughput screening platforms, stem cell technologies, and gene-edited cell platforms. They are applied across areas including drug discovery and development, toxicology and safety assessment, disease modeling, regenerative medicine, and basic research, and are used by end users including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, clinical and diagnostic laboratories, and government and public health agencies.

The cell-based biological reagents market consists of sales of cell lines, primary cells, stem cells, genetically engineered cell lines, reporter cell lines, cell-based assay kits, live cell reagents, frozen cell reagents, cell lysates, and cell culture ready cells. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.